Balanced news tone
News Sentiment
MDXG sentiment intelligence
MiMedx Group Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+4.1% over one week, +14.2% over four weeks, trend inactive, and below fair value.
Price to sales forward of MiMedx Group, Inc – NASDAQ:MDXG
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Price to sales forward of MiMedx Group, Inc – NASDAQ:MDXG
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:14
- Source
- TradingView
MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 20 Jun 2026 07:00
- Source
- Market source
MiMedx (NASDAQ: MDXG) awards 50,913 restricted shares to director
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Stock Titan
How The MiMedx Group (MDXG) Story Is Shifting As Analysts Rework Price Targets
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jun 2026 07:00
- Source
- Market source
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 12:45
- Source
- GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- PR Newswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Is the Options Market Predicting a Spike in MiMedx Group Stock?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 18:36
- Source
- Zacks
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
MiMedx: The Hard Math Behind My Downgrade To Hold
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 09 May 2026 07:00
- Source
- Seeking Alpha
MiMedx Launches G4Derm Plus Wound-Care Product Across US
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 12:44
- Source
- MT Newswires
MIMEDX Announces Launch of G4Derm® Plus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 12:00
- Source
- GlobeNewswire
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
How Reimbursement Shifts Are Rewriting The MiMedx Group (MDXG) Investment Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Market source
MiMedx Group, Inc. (NASDAQ:MDXG) Analysts Are Cutting Their Estimates: Here's What You Need To Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- Market source
MiMedx Group (MDXG) Launches CHORIOFIX Placental Allograft for Complex, Tunneling Wounds
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 09:22
- Source
- Insider Monkey
MIMEDX Announces First Quarter 2026 Operating & Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Apr 2026 07:00
- Source
- GlobeNewswire
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 29 Apr 2026 07:00
- Source
- Market source
Northland Reaffirms Outperform Rating for MiMedx Group (MDXG)
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 26 Apr 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
MiMedx (NASDAQ: MDXG) launches $40M savings plan amid Wound Care slowdown
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Stock Titan
MIMEDX cuts $40M in annual costs as wound-care recovery lags
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Stock Titan
How The MiMedx Group (MDXG) Story Is Shifting With Medicare And Analyst Revisions
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 05 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
MiMedx Group, Inc (MDXG) Stock Analysis: A Biotech Powerhouse with Nearly 100% Upside Potential
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Mar 2026 08:00
- Source
- DirectorsTalk Interviews